Objective:

To correct errors in the published case report regarding a NSCLC patient treated with alectinib.

Approach:

• Correction of Figures: The correction addresses errors in Figure 1 and Figure 3 of the original publication.

Key Findings:

• Figure 1 incorrectly labeled EML4::ALK as ML4::ALK.
• Figure 3 was mistakenly replaced with a duplicate of Figure 1.

Interpretation:

The original article has been updated to reflect these corrections.

Conclusion:

The corrected figures are now provided in the updated version of the article.

Sources:

• Frontiers in Oncology